| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/26/2009 | CA2174325C Non-antigenic branched polymer conjugates |
| 05/26/2009 | CA2091102C Microsomal triglyceride transfer protein |
| 05/22/2009 | WO2009065131A1 Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| 05/22/2009 | WO2009065130A2 Modified release formulations of diltiazem |
| 05/22/2009 | WO2009065126A2 Excipients for protein stabilization |
| 05/22/2009 | WO2009065098A1 Use of cathepsin k antagonists in the treatment of bone cancer |
| 05/22/2009 | WO2009065096A1 Mechanism-based small-molecule parasite inhibitors |
| 05/22/2009 | WO2009065090A2 Pharmaceutical compositions for the treatment of conditions responsive to proteasome inhibition |
| 05/22/2009 | WO2009065035A1 Therapeutic compounds and their use in treating diseases and disorders |
| 05/22/2009 | WO2009065028A2 Brca1-based breast or ovarian cancer prevention agents and methods of use |
| 05/22/2009 | WO2009065022A2 Low density lipoprotein receptor-mediated sirna delivery |
| 05/22/2009 | WO2009064983A1 Methods and compositions for treating dry eye |
| 05/22/2009 | WO2009064975A1 Quinoxaline-containing compounds as hepatitis c virus inhibitors |
| 05/22/2009 | WO2009064959A1 Isoquinoline modulators of atp-binding cassette transporters |
| 05/22/2009 | WO2009064955A1 Macrocyclic tetrazolyl hepatitis c serine protease inhibitors |
| 05/22/2009 | WO2009064953A1 Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases |
| 05/22/2009 | WO2009064943A1 Nucleic acid fluorescent stains |
| 05/22/2009 | WO2009064938A1 Method of treating arthritis |
| 05/22/2009 | WO2009064920A2 Compounds and methods for modulating protein expression |
| 05/22/2009 | WO2009064913A1 Chimer containing a targeting portion linked to a scission-activated duocarmycin-type prodrug |
| 05/22/2009 | WO2009064908A1 Cbi derivatives subject to reductive activation |
| 05/22/2009 | WO2009064852A1 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
| 05/22/2009 | WO2009064848A1 3-heterocyclic substituted indole derivatives and methods of use thereof |
| 05/22/2009 | WO2009064835A1 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors |
| 05/22/2009 | WO2009064819A2 Compositions for the treatment of gastrointestinal inflammation |
| 05/22/2009 | WO2009064792A1 Quinolone carboxylic acid-substituted rifamycin derivatives |
| 05/22/2009 | WO2009064752A2 Heterocyclic derivatives as modulators of ion channels |
| 05/22/2009 | WO2009064747A2 4(-3-(-2-(phenyl) morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl) benzenesulfon amide derivatives and related compounds as modulators of ion channels for the treatment of pain |
| 05/22/2009 | WO2009064738A2 Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| 05/22/2009 | WO2009064684A1 Substituted heterocyclic ethers and their use in cns disorders |
| 05/22/2009 | WO2009064681A2 Liquid compositions comprising valsartan |
| 05/22/2009 | WO2009064675A1 Mapk/erk kinase inhibitors |
| 05/22/2009 | WO2009064657A1 Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside |
| 05/22/2009 | WO2009064617A1 Stabilized glycosaminolglycan preparations and related methods |
| 05/22/2009 | WO2009064590A2 Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer |
| 05/22/2009 | WO2009064532A1 Compositions and methods for treating serous exudative effusion |
| 05/22/2009 | WO2009064505A1 Methods for treating visceral pain |
| 05/22/2009 | WO2009064493A1 Tricyclic compounds as melanogenesis modifiers and uses thereof |
| 05/22/2009 | WO2009064492A1 Quinoline compounds as melanogenesis modifiers and uses thereof |
| 05/22/2009 | WO2009064486A2 Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| 05/22/2009 | WO2009064485A1 Antioxidant flavonoid derivatives |
| 05/22/2009 | WO2009064479A1 Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
| 05/22/2009 | WO2009064471A1 Method of synthesis of morpholino oligomers |
| 05/22/2009 | WO2009064469A1 Pulmonary delivery of a macrolide antibiotic |
| 05/22/2009 | WO2009064465A1 Methods for treating and preventing bisphosphonate-induced osteonecrosis |
| 05/22/2009 | WO2009064459A2 Heterobifunctional polyethylene glycol reagents |
| 05/22/2009 | WO2009064458A2 Compositions for the treatment of inflammation of the gastrointestinal tract |
| 05/22/2009 | WO2009064457A2 Corticosteroid compositions |
| 05/22/2009 | WO2009064449A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 05/22/2009 | WO2009064444A2 Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| 05/22/2009 | WO2009064431A1 Methods of use |
| 05/22/2009 | WO2009064422A2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases |
| 05/22/2009 | WO2009064421A1 Histone deacetylase inhibitors as skin lightening agents |
| 05/22/2009 | WO2009064418A1 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| 05/22/2009 | WO2009064417A2 Compositions for the treatment of gastrointestinal inflammation |
| 05/22/2009 | WO2009064414A1 Beta-lactamase inhibitors |
| 05/22/2009 | WO2009064413A1 Beta-lactamase inhibitors |
| 05/22/2009 | WO2009064387A2 C4'-substituted-2-deoxyadenosine analogs and methods of treating hiv |
| 05/22/2009 | WO2009064374A2 Oral formulations of bis(thiohydrazide amides) |
| 05/22/2009 | WO2009064300A1 Combinations of hdac inhibitors and cytokines/growth factors |
| 05/22/2009 | WO2009064251A1 Bis-(sulfonylamino) derivatives in therapy 066 |
| 05/22/2009 | WO2009064250A1 Bis-(sulfonylamino) derivatives in therapy 065 |
| 05/22/2009 | WO2009064195A2 Reduced sexual maturation in fish |
| 05/22/2009 | WO2009064174A1 Polymorphic form of tenofovir disoproxil fumarate, method for its preparation and use |
| 05/22/2009 | WO2009064082A1 Composition comprising galla rhois extract for prevention and treatment of obesity by means of autophagic mechanism |
| 05/22/2009 | WO2009064004A1 Citrulline-containing drink |
| 05/22/2009 | WO2009063998A1 Nucleic acid having hydrophobic substance added thereto, and use thereof |
| 05/22/2009 | WO2009063993A1 Fused pyridine derivative and use thereof |
| 05/22/2009 | WO2009063992A1 Condensed pyridine derivative and use thereof |
| 05/22/2009 | WO2009063991A1 Pyridooxazepine derivative and use thereof |
| 05/22/2009 | WO2009063990A1 Benzazepinone compound |
| 05/22/2009 | WO2009063953A1 Phenylpyrazole derivatives |
| 05/22/2009 | WO2009063931A1 Method for evaluation of blood circulation-promoting activity, method for screening of blood circulation-promoting substance, and blood circulation promoter |
| 05/22/2009 | WO2009063897A1 Prophylactic or ameliorating agent for psoriasis in the skin |
| 05/22/2009 | WO2009063836A1 Process for production of polyphenol extract, prophylactic agent for osteoporosis, saccharide-digesting enzyme inhibitor, functional composition comprising the polyphenol extract, and food composition, food composition for specified health uses, quasi drug composition and pharmaceutical composition each comprising the functional composition |
| 05/22/2009 | WO2009063821A1 Heteroaryloxy quinazoline derivative |
| 05/22/2009 | WO2009063782A1 Composition for external application to skin |
| 05/22/2009 | WO2009063522A1 Composition for the treatment of hypertrophic scars comprising fucose, dimethylsulfone and/or acetyl glucosamine |
| 05/22/2009 | WO2009063493A2 Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid |
| 05/22/2009 | WO2009063492A2 Novel agents for treatment of ailments and dysfunctions |
| 05/22/2009 | WO2009063491A2 Topical compositions for skincare |
| 05/22/2009 | WO2009063485A2 Treatments using vitamin k analogues and derivatives |
| 05/22/2009 | WO2009063484A2 Stable pharmaceutical composition of lamotrigine |
| 05/22/2009 | WO2009063476A1 A crystalline form of atorvastatin hemi magnesium salt and a process thereof |
| 05/22/2009 | WO2009063440A1 Compositions comprising stilbene polyphenol derivatives and use thereof for combating the ageing of living organisms and diseases affecting same |
| 05/22/2009 | WO2009063439A1 Compositions containing flavanoid polyphenol derivatives, and applications thereof in controlling diseases and ageing of living organisms |
| 05/22/2009 | WO2009063427A1 Dioxoanthracene sulphonate derivatives |
| 05/22/2009 | WO2009063412A1 Use of chemical compounds for the treatment of aids |
| 05/22/2009 | WO2009063378A2 Olive oil formulation for pain relief |
| 05/22/2009 | WO2009063365A1 Azetidines as ep2 antagonists |
| 05/22/2009 | WO2009063320A2 Solid pharmaceutical composition of ded anosine |
| 05/22/2009 | WO2009063301A1 Sphingosine- 1- phosphate (s1p) receptor compounds |
| 05/22/2009 | WO2009063248A2 Polymorphic forms of tegaserod glutarate |
| 05/22/2009 | WO2009063247A1 Novel crystalline forms |
| 05/22/2009 | WO2009063244A1 Pyridazinone derivatives as parp inhibitors |
| 05/22/2009 | WO2009063241A1 3-hydroxyanthranilic acid or salts thereof1 for treating cancer or infections |
| 05/22/2009 | WO2009063240A1 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| 05/22/2009 | WO2009063235A1 Derivatives of 1,9-dihydro-6h-purin-6-one and uses thereof-018 |
| 05/22/2009 | WO2009063226A2 Methods relating to breathing disorders |
| 05/22/2009 | WO2009063223A1 Use of anti-bacterial compounds having an anaesthetic effect |